TD Cowen raised the firm’s price target on HCA Healthcare to $450 from $375 and keeps a Buy rating on the shares. The firm raised its target in conjunction with their State Directed Payment (SDP) being underappreciated. The consensus EBITDA estimates over the next 3-12 months may move close to +10% or higher as the acceleration of SDP expansion is more readily apparent.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare initiated with an Overweight at KeyBanc
- HCA Healthcare initiated with an Equal Weight at Morgan Stanley
- HCA Healthcare price target raised to $405 from $378 at RBC Capital
- HCA Healthcare price target raised to $430 from $390 at Truist
- HCA Healthcare participates in a conference call hosted by Truist